Background There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which subsequent treatment oncologists prefer in patients with disease progression under CDKi. In addition, we aimed to show the effectiveness of systemic treatments after CDKi and whether there is a survival difference between hormonal treatments (monotherapy vs. mTOR-based). Methods A total of 609 patients from 53 centers were included in the study. Progression-free-survivals (PFS) of subsequent treatments (chemotherapy (CT, n:434) or endocrine therapy (ET, n:175)) after CDKi were calculated. Patients were evaluated in three groups as those who received CDKi in first-line (group A, n:202), second-line (group B, n: 153) and ≥ 3rd-line (group C, n: 254). PFS was compared according to the use of ET and CT. In addition, ET was compared as monotherapy versus everolimus-based combination therapy. Results The median duration of CDKi in the ET arms of Group A, B, and C was 17.0, 11.0, and 8.5 months in respectively; it was 9.0, 7.0, and 5.0 months in the CT arm. Median PFS after CDKi was 9.5 (5.0–14.0) months in the ET arm of group A, and 5.3 (3.9–6.8) months in the CT arm (p = 0.073). It was 6.7 (5.8–7.7) months in the ET arm of group B, and 5.7 (4.6–6.7) months in the CT arm (p = 0.311). It was 5.3 (2.5–8.0) months in the ET arm of group C and 4.0 (3.5–4.6) months in the CT arm (p = 0.434). Patients who received ET after CDKi were compared as those who received everolimus-based combination therapy versus those who received monotherapy ET: the median PFS in group A, B, and C was 11.0 vs. 5.9 (p = 0.047), 6.7 vs. 5.0 (p = 0.164), 6.7 vs. 3.9 (p = 0.763) months. Conclusion Physicians preferred CT rather than ET in patients with early progression under CDKi. It has been shown that subsequent ET after CDKi can be as effective as CT. It was also observed that better PFS could be achieved with the subsequent everolimus-based treatments after first-line CDKi compared to monotherapy ET.

Introduction Coronavirus related lockdown measures had a severe psychological toll. We investigated the effects of population‐wide infection control measures on hemodialysis (HD) and oncology patients' mood statuses. Methods An electronic survey was used to collect data. We used the Profile of Mood States (POMS) and the Hospital Anxiety and Depression Scale (HADS) to measure the mood statuses. Results The study groups composed of 400 HD, 234 oncology patients, and 276 controls. HADS anxiety and total POMS scores were significantly higher in the control group than that of both HD and oncology patients, a finding consistent with a worse mood status. In multivariate models, the male gender and the perception of having received appropriate medical support during the pandemic period were independent predictors of better POMS and HADS‐anxiety and depression scores. Conclusion HD and oncology patients appear to be less affected by the psychological stress induced by social distancing and lockdown periods.

Background As a result of technological developments in healthcare services, telemedicine is becoming widespread. We aimed to determine the effect of COVID-19 on Turkish medical oncologists’ opinions of telemedicine through a survey. Methods This study was conducted using an online questionnaire linked to an invitation e-mail sent to the members of the Turkish Medical Oncology Association mailing group between May and July 2020. Results Of the 110 (73 males and 37 females) medical oncologists who answered the questionnaire, the average age was 43.9 ± 7.29 (range: 31–64) years, and the majority of the respondents were academics. The most commonly used telemedicine method was store and forward (69.7%). Telemedicine use during clinical visits and multidisciplinary councils increased significantly during the COVID-19 pandemic ( p < 0.001 in both cases). Conclusion The use of telemedicine increased during the COVID-19 pandemic, and the pandemic has led oncologists to view telemedicine more positively.

This study indicates that patients with WD have differences in the anterior segment parameters including central corneal thickness, keratometric values, anterior and posterior elevations, horizontal visible iris diameter, and anterior chamber depth when compared with healthy controls.

Amaç: Medulloblastom çocukluk çağında sık görülen beyin tümörlerinden biridir. Erişkin yaşta ise çok nadir olarak görülmektedir. Bu çalışmamızda medulloblastom tanılı hastalarımızın klinik ve patolojik özelliklerini paylaşmayı amaçladık Yöntemler: 2010 Kasım ile 2020 Nisan ayı arasında medulloblastom tanısı alan 28 hasta çalışmaya dahil edilmiştir. Hasta dosya sistemin-den yaş, cinsiyet, tanı tarihi, ex tarihi, progresyon tarihi, tümör lokalizasyonu, tümör histopatolojik alt tipi, cerrahi şekli verileri kaydedildi. Hastaların 5 yıllık ortalama sağkalım ve progresyonsuz sağkalım oranları hesaplandı. Bulgular: Hastaların ortalama yaşı 32 idi. 16 hasta erkek 12 si ise kadındı. Histopatolojik özelliklerine bakıldığında 17 hasta klasik varyant, 11 hasta ise desmoplastik histopatolojiye sahipti. 15 has-tada nüks saptanırken 13 hasta nüks bulgusuna rastlanılmadı. 28 hastanın 16’sı yaşıyor 12 hasta ise ex olmuştu. Hastaların 5 yıllık OS %59,4, 5 yıllık PFS ise %42,3 idi Sonuç: Medulloblastom erişkin dönemde çok nadir olarak görüldüğü için bu hastalık ile ilgili yeterli veri bulunmamaktadır. Komplet rezeksiyon bu hastalarda sağkalım açısından büyük önem içermektedir.